Actavis to Appeal Ruling Regarding Namenda IR Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 5:20PM CST
Actavis plc (ACT) announced its decision to file an emergency appeal for an immediate overturn of the lower court ruling that will require the company to continue selling Namenda IR.
IPXL: 29.09 (-1.55), ACT: 256.52 (-6.48), AKRX: 37.55 (-2.17), MYL: 53.56 (-0.96)
Stocks Mixed In Volatile Session; Boeing Boosts Dow
at Investor's Business Daily - Tue Dec 16, 2:04PM CST
Stocks wavered and were mixed heading into the final hour Tuesday. The Dow clung to a 0.2% gain, while the S&P 500 added a fraction and the Nasdaq fell 0.4%. Volume was tracking mildly higher across the board. The Russell 2000 outperformed in the...
AKRX: 37.55 (-2.17), BA: 124.25 (+2.17), BCPC: 65.24 (+1.89), MMS: 51.00 (+0.67)
Great Stocks: Drugmaker Akorn Works On Base
at Investor's Business Daily - Mon Dec 15, 5:33PM CST
Generic-drug maker Akorn is among a few stocks in the Spotlight screen that is working on a base. Even better, the pattern is second stage, which has a better chance of success than a base that forms later in a stock's advance. The potential buy...
AKRX: 37.55 (-2.17)
Insider Trading Alert - AHC, AKRX And CNBKA Traded By Insiders
at The Street - Mon Dec 15, 9:30AM CST
Stocks with insider trader activity include AHC, AKRX and CNBKA
CNBKA: 39.89 (+0.54), AHC: 12.17 (-0.03), AKRX: 37.55 (-2.17)
Why Akorn (AKRX) is Poised to Beat Earnings Estimates Again - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 8:03AM CST
Akorn has seen a nice streak of beating earnings estimates at the previous two reports and might be in a good position to beat earnings at its next report
AKRX: 37.55 (-2.17)
Actavis Likely to Continue Selling Namenda IR Tablets - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 2:20PM CST
Actavis plc (ACT) may face an injunction under which the company will have to continue selling Namenda IR.
IPXL: 29.09 (-1.55), ACT: 256.52 (-6.48), AKRX: 37.55 (-2.17), MYL: 53.56 (-0.96)
Technical Data on Pharma Stocks - Pfizer, Merck, AbbVie, Akorn, and The Medicines
PR Newswire - Fri Dec 12, 8:10AM CST
Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Merck and Company Inc. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), Akorn Inc. (NASDAQ: AKRX), and The Medicines Company (NASDAQ: MDCO). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, December 11, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,596.34, up 0.36% and the NASDAQ Composite closed at 4,708.16, up 0.52%. The S&P 500 finished the session 0.45% higher at 2,035.33. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 806.11, up 0.26%, with the index advancing 8.67% in the previous three months. Register for your complimentary reports on these five stocks at:
MDCO: 26.38 (+1.24), AKRX: 37.55 (-2.17), MRK: 56.80 (-0.15), PFE: 30.67 (-0.19), ABBV: 65.25 (-0.37)
Supernus Faces another Patent Challenge for Oxtellar XR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 2:20PM CST
Supernus Pharmaceuticals, Inc. (SUPN) received a Para IV notice from TWi Pharma, seeking approval for its generic version of Supernus' Oxtellar XR in the U.S.
ACT: 256.52 (-6.48), AKRX: 37.55 (-2.17), SUPN: 8.72 (+0.08), MYL: 53.56 (-0.96)
Supernus Faces New Patent Challenge for Trokendi XR - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 10, 1:50PM CST
Supernus Pharmaceuticals, Inc. (SUPN) received a Paragraph IV notice from Par, which is looking to get its generic version of Supernus' Trokendi XR approved in the U.S.
ACT: 256.52 (-6.48), AKRX: 37.55 (-2.17), SUPN: 8.72 (+0.08), MYL: 53.56 (-0.96)
Energy Sector Drags On Stocks; Lakeland, Spirit, Akorn Rise
at Investor's Business Daily - Wed Dec 10, 9:28AM CST
Stocks opened in the hole Wednesday, posting quiet losses as energy stocks suffered many of the largest early declines. The Dow Jones industrial average and the S&P 500 each slipped 0.6%. The Nasdaq shed 0.4%. Volume was sharply lower, as the stock...
SAVE: 68.70 (+0.11), AKRX: 37.55 (-2.17), COST: 137.31 (-0.88), LAKE: 9.19 (-0.46), XOM: 86.41 (-0.49), VRA: 20.11 (+0.33), FRAN: 15.97 (+0.03), KKD: 19.35 (+0.06), CVX: 101.70 (+0.84), TOL: 30.92 (-0.28), HOV: 3.78 (-0.24)
Akorn Rises 3.50% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Dec 09, 5:10PM CST
Akorn (NASDAQ:AKRX) traded in a range yesterday that spanned from a low of $39.01 to a high of $41.31. Yesterday, the shares gained 3.5%, which took the trading range above the 3-day high of $40.50 on volume of 2.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AKRX: 37.55 (-2.17)
Stocks Snap Back After Morning Downdraft; AutoZone Jumps
at Investor's Business Daily - Tue Dec 09, 3:16PM CST
Major averages recovered early losses Tuesday, an impressive performance considering the carnage in overseas markets overnight. At the close, the Nasdaq turned a 1.4% intraday loss into a 0.5% gain. The S&P 500 also fell more than 1% in the morning...
T: 32.14 (-0.11), BIDU: 219.96 (-5.85), SAVE: 68.70 (+0.11), AAP: 157.01 (-4.00), AZO: 597.93 (-7.91), AKRX: 37.55 (-2.17), ORLY: 190.17 (-2.04), DATA: 80.32 (-1.26), VZ: 45.53 (+0.11), BABA: 105.77 (+1.07)
Stocks Recover After Sharp Losses; Nasdaq Turns Positive
at Investor's Business Daily - Tue Dec 09, 2:01PM CST
Major averages recovered well above session lows Tuesday, an impressive performance amid a sell-off in China and European markets. The Dow Jones industrial average lost 0.5%, weighed down by Verizon (VZ) and AT&T (T). The S&P 500 eased 0.3% after...
CAVM: 58.14 (-1.02), T: 32.14 (-0.11), SAVE: 68.70 (+0.11), AZO: 597.93 (-7.91), AKRX: 37.55 (-2.17), HQY: 22.74 (-0.16), VZ: 45.53 (+0.11)
Stocks Swoon In Heavy Trade; Spirit Airlines Spirals Lower
at Investor's Business Daily - Tue Dec 09, 9:38AM CST
Stocks opened to broad and breathtaking losses Tuesday, as harsh selling overseas and weakened energy prices took a bite out of investor confidence. The Nasdaq tumbled 1.1% at the starting bell. The S&P 500 and the Dow Jones industrial average fell...
AMBA: 45.78 (-0.35), TSLA: 197.81 (-6.23), MNST: 106.24 (+1.23), GPRO: 58.27 (+1.27), CAVM: 58.14 (-1.02), AKRX: 37.55 (-2.17), KFY: 27.84 (+0.67), SAVE: 68.70 (+0.11), HQY: 22.74 (-0.16), MRK: 56.80 (-0.15), KKD: 19.35 (+0.06), VZ: 45.53 (+0.11)
Actavis' Antibiotic Backed for FDA Approval, Response in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 5:30PM CST
Actavis' (ACT) ceftazidime-avibactam got favorable recommendation from the Anti-Infective Drugs Advisory Committee for the treatment of complicated intra-abdominal infections and complicated urinary tract infections.
ACT: 256.52 (-6.48), CBST: 96.73 (+0.42), AKRX: 37.55 (-2.17), AZN: 69.56 (-0.18)
Stocks Sink In Late Trading: Tesla, McDonald's Dive
at Investor's Business Daily - Mon Dec 08, 2:06PM CST
Stocks stretched losses heading into the final hour of trading Monday. In the stock market today the Nasdaq fell 0.9%, the S&P 500 dropped 0.7%, and the Dow trimmed 0.6%. Volume was tracking higher across the board compared with Friday's levels. From...
TSLA: 197.81 (-6.23), AKRX: 37.55 (-2.17), UTX: 113.23 (+1.32), JAZZ: 159.65 (-2.95), MCD: 88.72 (+0.26), CELG: 110.09 (-1.79)
Stock Market Today: Jazz Hits New High, In Buy Range
at Investor's Business Daily - Mon Dec 08, 11:02AM CST
Stocks were lower at midday Monday following mixed overseas economic data. The Nasdaq was up 0.1%, while the S&P 500 and the Dow Jones industrial average were each off a fraction. Volume was tracking lower on both major exchanges in the stock market...
ANET: 68.34 (+0.95), GILD: 100.46 (-2.70), AKRX: 37.55 (-2.17), JAZZ: 159.65 (-2.95), TASR: 22.85 (-0.02), CSCO: 26.58 (-0.10), CELG: 110.09 (-1.79)
Akorn (AKRX) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 8:10AM CST
Akorn (AKRX) Sees Hammer Chart Pattern: Time to Buy?
AKRX: 37.55 (-2.17)
Actavis Launches Generic of Shire's ADHD Drug Intuniv - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 5:45PM CST
Actavis (ACT) launched its generic version of Shire's attention deficit hyperactivity disorder drug Intuniv in the U.S.
AGN: 205.75 (-3.26), ACT: 256.52 (-6.48), AKRX: 37.55 (-2.17), SHPG: 208.76 (+0.28)
Teva First to Launch a Generic of Novartis' Exforge HCT - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 3:30PM CST
Teva (TEVA), which has launched its generic version of Novartis' Exforge HCT in the U.S., will enjoy 180 days exclusivity.
AKRX: 37.55 (-2.17), MYL: 53.56 (-0.96), TEVA: 55.15 (-0.47), NVS: 91.65 (+0.01)